Anti-MYLK3 monoclonal antibody

Pre-made anti-MYLK3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MYLK3/MYLK3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1227-Ab-1/ GM-Tg-hg-IP1227-Ab-2Anti-Human MYLK3 monoclonal antibodyHuman
GM-Tg-rg-IP1227-Ab-1/ GM-Tg-rg-IP1227-Ab-2Anti-Rat MYLK3 monoclonal antibodyRat
GM-Tg-mg-IP1227-Ab-1/ GM-Tg-mg-IP1227-Ab-2Anti-Mouse MYLK3 monoclonal antibodyMouse
GM-Tg-cynog-IP1227-Ab-1/ GM-Tg-cynog-IP1227-Ab-2Anti-Cynomolgus/ Rhesus macaque MYLK3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1227-Ab-1/ GM-Tg-felg-IP1227-Ab-2Anti-Feline MYLK3 monoclonal antibodyFeline
GM-Tg-cang-IP1227-Ab-1/ GM-Tg-cang-IP1227-Ab-2Anti-Canine MYLK3 monoclonal antibodyCanine
GM-Tg-bovg-IP1227-Ab-1/ GM-Tg-bovg-IP1227-Ab-2Anti-Bovine MYLK3 monoclonal antibodyBovine
GM-Tg-equg-IP1227-Ab-1/ GM-Tg-equg-IP1227-Ab-2Anti-Equine MYLK3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1227-Ab-1/ GM-Tg-hg-IP1227-Ab-2; GM-Tg-rg-IP1227-Ab-1/ GM-Tg-rg-IP1227-Ab-2;
GM-Tg-mg-IP1227-Ab-1/ GM-Tg-mg-IP1227-Ab-2; GM-Tg-cynog-IP1227-Ab-1/ GM-Tg-cynog-IP1227-Ab-2;
GM-Tg-felg-IP1227-Ab-1/ GM-Tg-felg-IP1227-Ab-2; GM-Tg-cang-IP1227-Ab-1/ GM-Tg-cang-IP1227-Ab-2;
GM-Tg-bovg-IP1227-Ab-1/ GM-Tg-bovg-IP1227-Ab-2; GM-Tg-equg-IP1227-Ab-1/ GM-Tg-equg-IP1227-Ab-2
Products NameAnti-MYLK3 monoclonal antibody
Formatmab
Target NameMYLK3
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MYLK3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1227-Ag-1Recombinant multi-species MYLK3/ MLCK/ MLCK2 protein
    ORF Viral VectorpGMAD000515human MYLK3 Adenovirus plasmid
    ORF Viral VectorvGMAD000515human MYLK3 Adenovirus particle


    Target information

    Target IDGM-IP1227
    Target NameMYLK3
    Gene ID91807,213435,291926,716132,475345,101091744,526379,100056559
    Gene Symbol and SynonymscaMLCK,D830007F02Rik,MLCK,MLCK2,MYLK3,RGD1305801
    Uniprot AccessionQ32MK0,E9PT87
    Uniprot Entry NameMYLK3_HUMAN,MYLK3_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000140795
    Target ClassificationKinase

    The target: MYLK3, gene name: MYLK3, also named as MLCK, MLCK2, caMLCK. Phosphorylation of cardiac myosin heavy chains (see MYH7B, MIM 609928) and light chains (see MYL2, MIM 160781) by a kinase, such as MYLK3, potentiates the force and rate of cross-bridge recruitment in cardiac myocytes (Chan et al., 2008 [PubMed 18202317]).[supplied by OMIM, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.